China Health Group Inc., an investment holding company, provides clinical research services to pharmaceutical and biotechnology companies in the People’s Republic of China.
Price History & Performance
|Historical stock prices|
|Current Share Price||HK$0.49|
|52 Week High||HK$0.33|
|52 Week Low||HK$0.70|
|1 Month Change||30.26%|
|3 Month Change||17.86%|
|1 Year Change||3.13%|
|3 Year Change||163.30%|
|5 Year Change||132.39%|
|Change since IPO||20.73%|
Recent News & Updates
Should You Be Adding China Health Group (HKG:8225) To Your Watchlist Today?
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...
|8225||HK Life Sciences||HK Market|
Return vs Industry: 8225 underperformed the Hong Kong Life Sciences industry which returned 90.1% over the past year.
Return vs Market: 8225 underperformed the Hong Kong Market which returned 7.3% over the past year.
Stable Share Price: 8225 is not significantly more volatile than the rest of Hong Kong stocks over the past 3 months, typically moving +/- 8% a week.
Volatility Over Time: 8225's weekly volatility (8%) has been stable over the past year.
About the Company
China Health Group Inc., an investment holding company, provides clinical research services to pharmaceutical and biotechnology companies in the People’s Republic of China. The company offers contracted clinical research services; contracted pharmaceutical development services; post launch market research, medical, and medical market services; medical science liaisons; and other medical services. It also provides hospital management, medical tourism, and specialized hospital services, as well as Venturepharma cloud; and sells drugs technologies.
China Health Group Fundamentals Summary
|8225 fundamental statistics|
Is 8225 overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|8225 income statement (TTM)|
|Cost of Revenue||CN¥16.70m|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||0.062|
|Net Profit Margin||69.32%|
How did 8225 perform over the long term?See historical performance and comparison
Is China Health Group undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: 8225 (HK$0.5) is trading above our estimate of fair value (HK$0.46)
Significantly Below Fair Value: 8225 is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: 8225 is good value based on its PE Ratio (6.6x) compared to the Hong Kong Life Sciences industry average (50.6x).
PE vs Market: 8225 is good value based on its PE Ratio (6.6x) compared to the Hong Kong market (10.2x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 8225's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 8225 is good value based on its PB Ratio (2.9x) compared to the HK Life Sciences industry average (6.6x).
How is China Health Group forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as China Health Group has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has China Health Group performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 8225 has a high level of non-cash earnings.
Growing Profit Margin: 8225's current net profit margins (69.3%) are higher than last year (46.5%).
Past Earnings Growth Analysis
Earnings Trend: 8225's earnings have grown significantly by 41% per year over the past 5 years.
Accelerating Growth: 8225's earnings growth over the past year (79.9%) exceeds its 5-year average (41% per year).
Earnings vs Industry: 8225 earnings growth over the past year (79.9%) exceeded the Life Sciences industry 57.3%.
Return on Equity
High ROE: 8225's Return on Equity (43.4%) is considered outstanding.
How is China Health Group's financial position?
Financial Position Analysis
Short Term Liabilities: 8225's short term assets (CN¥183.6M) exceed its short term liabilities (CN¥42.8M).
Long Term Liabilities: 8225 has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: 8225 is debt free.
Reducing Debt: 8225 currently has no debt however we can't compare to 5 years ago as we have no data for that period.
Debt Coverage: 8225 has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: 8225 has no debt, therefore coverage of interest payments is not a concern.
What is China Health Group current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate 8225's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate 8225's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if 8225's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 8225's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of 8225's dividend in 3 years as they are not forecast to pay a notable one for the Hong Kong market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
China Health Group has no CEO, or we have no data on them.
Experienced Management: 8225's management team is seasoned and experienced (5.4 years average tenure).
Experienced Board: 8225's board of directors are considered experienced (3.6 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
China Health Group Inc.'s employee growth, exchange listings and data sources
- Name: China Health Group Inc.
- Ticker: 8225
- Exchange: SEHK
- Founded: 1998
- Industry: Life Sciences Tools and Services
- Sector: Pharmaceuticals & Biotech
- Market Cap: HK$492.699m
- Shares outstanding: 995.35m
- Website: https://www.chgi.net
Number of Employees
- China Health Group Inc.
- Building 17
- Jianwai SOHO
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/09/16 15:29|
|End of Day Share Price||2021/09/16 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.